hemophagocytic lymphohistiocytosis
Jul 01, 2025
Sobi’s GAMIFANT Approved by FDA as First Treatment for Macrophage Activation Syndrome in Still’s Disease; GSK Cuts RTS,S Malaria Vaccine Price for Children in Endemic Regions to Under $5; Schrödinger’s SGR-1505 Receives FDA Fast Track Designation for Relapsed/Refractory Waldenström Macroglobulinemia; Ultragenyx’s GTX-102 Granted FDA Breakthrough Therapy Designation for Angelman Syndrome; Eli Lilly’s AMYVID Label Updated by FDA to Support Alzheimer’s Disease Diagnosis
FDA Approves Sobi’s GAMIFANT as the First Treatment for Macrophage Activation Syndrome in Still’s Disease In a major advancement for rare inflammatory conditions, the FDA has approved GAMIFANT (emapalumab-lzsg) for the treatment of hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MA...
Read More...
Jan 25, 2021
A Bleak Pipeline and Lack of Approved Treatment Clouds the Hemophagocytic Lymphohistiocytosis Market Size Growth
Having a strong immune system, flourished with properly working immune cells is the ultimate key to surviving a healthy life. However, what if a person is in possession of overactive immune cells? It leads to improper functioning of the immune system, confusing internal organs as foreign invaders thus attacking the...
Read More...
Nov 22, 2018
Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates
Cambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions with a deal of USD 250 million to become a leading contract development and manufacturing organization (CDMO). The agreement includes the early-stage drug development and manufacturing capabi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
